TITLE

Use of histological and genetic markers in optimizing therapy for patients with non-small-cell lung cancer

PUB. DATE
January 2010
SOURCE
American Journal of Health-System Pharmacy;1/1/2010, Vol. 67 Issue 1, pS15
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A quiz concerning the use of histological and genetic markers in the therapy optimization of non-small-cell lung cancer patients.
ACCESSION #
47427235

 

Related Articles

  • Use of histological and genetic markers in optimizing therapy for patients with non-small-cell lung cancer. Adams, Val R.; Sheth, Sheetal // American Journal of Health-System Pharmacy;1/1/2010, Vol. 67 Issue 1, pS1 

    The article discusses the use of histological and genetic markers in the therapy optimization of non-small-cell lung cancer (NSCLC) patients in the U.S. Study demonstrates that the response to therapy among these patients may differ for patients with adenocarcinoma versus squamous cell...

  • Use of histological and genetic markers in optimizing therapy for patients with non-small-cell lung cancer. Adams, Val R.; Harvey, R. Donald // American Journal of Health-System Pharmacy;1/1/2010, Vol. 67 Issue 1, pS3 

    Purpose. To describe how molecular and genetic markers influence the response to therapy in patients with advanced nonsmall- cell lung cancer (NSCLC). Summary. Cisplatin resistance has been associated with high rates of expression of endonucleases, a family of DNA repair proteins that includes...

  • Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588... Sause, William T.; Scott, Charles // JNCI: Journal of the National Cancer Institute;2/1/95, Vol. 87 Issue 3, p198 

    Reports on the results of clinical trials conducted by the Radiation Therapy Oncology Group (RTOG) and the Eastern Cooperative Oncology Group (ECOG) using innovative radiation delivery techniques and the addition of chemotherapy in the treatment of non-small cell lung cancer. Acceptable...

  • Lung cancer: Treating the untreatable.  // Patient Care;3/15/1998, Vol. 32 Issue 5, p18 

    Presents information on lung cancer and its treatment. Reference to lung cancer being the greatest neoplastic killer of Americans; Relation to photodynamic treatment with porfimer sodium (Photofrin) being approved by the Food and Drug Administration (FDA) for inoperable esophageal cancer;...

  • Veggies may shield women against cancer... Capwell, Martha // Prevention;Oct92, Vol. 44 Issue 10, p36 

    Reports that a diet rich in vegetables and high in carotene is linked to lower risk of lung cancer in nonsmokers. Evidence found by epidemiologists in Florida in 124 women with lung cancer; Heavy consumption of both vegetables and fruits reduce the risk of breast cancer.

  • Wider use of lung cancer drug.  // FDA Consumer;Jul/Aug94, Vol. 28 Issue 6, p3 

    Reports that the wider use of Vinorelbine tartrate, an investigational lung cancer drug, has been approved by the Food and Drug Administration (FDA). Plans to market the drug under the name Navelbine; Investigational New Drug (IND) regulations.

  • Re: Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized... Pfeiffer, Per; Rytter, Carsten; Madsen, Ebbe Lindegaard; Moeholt, Kirsten; Hansen, Olfred; Bentzen, Soren; Palshof, Torben; Rose, Carsten // JNCI: Journal of the National Cancer Institute;12/17/97, Vol. 89 Issue 24, p1892 

    Investigates whether single-agent, daily, oral etoposide is an effective, palliative therapy for advanced small-cell lung cancer as compared with combination therapy. Bioavailability of oral etoposide; Comparison of tumor response to oral etoposide and combination therapy in patients with...

  • Substance in tree bark could lead to new lung cancer treatment.  // Edgewood Enterprise (TX);7/26/2007, Vol. 100 Issue 30, p8 

    The article cites key research findings from the University of Texas Southwestern Medical Center in 2007 indicating that beta-lapachone from the South American lapacho tree's bark can eliminate certain types of lung cancer cells.

  • Crizotinib.  // Reactions Weekly;2/4/2012, Issue 1387, p15 

    The article describes the cases of three patients with non-small cell lung cancer who developed sinus bradycardia while receiving oral crizotinib 250 milligrams (mg) twice daily.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics